In the subject population for this cross-sectional study, the SARS-CoV-2 infection rate (23% to 56%) and the comorbidity rate (5.8% to 15.8%) rose significantly from 2021 to 2022, a time when SARS-CoV-2 vaccination coverage (67% to 92.9%) also rose significantly.
"Abstract ...
Methods: We present an observational, descriptive, cross-sectional study aimed at identifying SARS-CoV-2 variants circulating during two local waves of COVID-19 cases in southern Bahia, Brazil (late 2021 and late 2022), and analyzing the association between the detected variants and the epidemiological and clinical characteristics of the disease...
Results
General characteristics of the study population
... We observed an important difference in the positive rate for SARS-CoV-2, being much higher in 2022 (56%) than in 2021 (23%). Besides, a low frequency of individuals with comorbidities were observed (5.8% and 15.8% in 2021 and 2022, respectively) (Table 1). As expected, a higher coverage of SARS-CoV-2 vaccination was observed in 2022 with 92.9% of the individuals fully vaccinated and none unvaccinated, whereas, in 2021, 67% were fully vaccinated and around 7% were not vaccinated.¨
© The Author(s) 2024. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.